Physician profile
Pill Raja
NPI 1518927656
$3,065.39
in general payments reported to CMS, 2019-2025
27 companies · $64.35 in 2025
The $64.35 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,088 · 2020: $210 · 2021: $485 · 2022: $559 · 2023: $461 · 2024: $198 · 2025: $64.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $534 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $533.99 |
| Education | $188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $984.95 | 2019-2021 | |
| Abbvie INC. | $678.76 | 2019-2025 | |
| Astellas Pharma US INC | $558.14 | 2019-2024 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $255.70 | 2022-2023 | Slynd, Nuvessa |
| Urovant Sciences INC | $54.28 | 2022 | |
| Merck Sharp & Dohme LLC | $47.23 | 2021-2023 | Bridion |
| Lilly USA, LLC | $42.22 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Avion Pharmaceuticals | $37.67 | 2019-2021 | |
| Coopersurgical, INC. | $34.26 | 2019-2020 | |
| Agile Therapeutics, INC. | $33.17 | 2021 | |
| Boston Scientific Corporation | $31.64 | 2020 | |
| Allergan, INC. | $31.16 | 2019 | |
| Amgen INC. | $29.88 | 2020-2022 | |
| Hologic Sales and Service, LLC | $25.20 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.34 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $20.31 | 2019 | |
| Abbott Laboratories | $20.14 | 2022 | |
| Organon LLC | $18.48 | 2024 | |
| Sumitomo Pharma America, INC. | $18.38 | 2023 | Gemtesa |
| Coloplast Corp | $17.37 | 2021 | |
| Shield Therapeutics INC | $17.24 | 2023 | Accrufer |
| Laborie Medical Technologies Corp. | $16.73 | 2021 | |
| Gilead Sciences, INC. | $15.45 | 2019 | |
| Mayne Pharma Commercial LLC | $15.30 | 2025 | |
| Novo Nordisk INC | $15.11 | 2023 | Wegovy, Saxenda |
| Acessa Health INC. | $14.51 | 2020 | |
| Lupin INC. | $11.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pill Raja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.